Theriva Biologics Inc
therivabio.comWhat Do They Do?
Develops oncolytic-virus drug candidates for cancer patients, including candidates intended to work with chemotherapy or immunotherapy.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$3.2MView ↗
- ▼ −75% (Loss)
- vs −$13.1M in Q2 FY2025
Who Do They Compete With?
Competes with Amgen, Daiichi Sankyo, Shanghai Sunway Biotech, Replimune, CG Oncology, AdCure Bio, Calidi Biotherapeutics, Candel Therapeutics, Elicera Therapeutics, EpicentRx, GeneMedicine, Lokon Pharma, Memgen, NewGenPharm, Oncolys BioPharma, Orca Therapeutics, Akamis Bio, Theolytics, TILT Biotherapeutics, and UroGen Pharma
10-K for FY2025, filed Mar 12, 2026Only three OV products have been approved in different global markets. Amgen Inc.’s Imlygic® (T-VEC, OncoVEX) for melanoma (USA); Daiichi…View ↗
Loading...
